Pharmacology and clinical experience with exemestane

Bibliography

• CLARKE M, COLLINS R, DAVIES C, GODWIN J, GRAY R, PETO R: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351 (9114):1451–1467.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis confirming the benefits of adjuvant tamoxifenfor variable duration.
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (1998) 90(18):1371–1388.
   PubMed Web of Science ®Google Scholar
• ••Showing the benefit of breast cancer prevention withtamoxifen.
   Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA et al: The effect of raloxifene on risk of breast cancer in postmeno-pausal women. Results from the MORE randomized trial. JAMA (1999) 281 (23):2189–2197.
   PubMed Web of Science ®Google Scholar
• ••Showing the benefit of breast cancer prevention withraloxifene.
   Google Scholar
• BEATSON GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet (1896) 2:104–107.
   Google Scholar
• DAO TL, HUGGINS C: Bilateral adrenalectomy in the treatment of cancer of the breast. Arch. Surg. (1955) 71:645–657.
   Web of Science ®Google Scholar
• LUFT R, OLIVECRONA H, SJOGREN B: Hypophysektomyin man. Nord. Med. (1952) 14:351–354.
   Google Scholar
• LONNING PE, DOWSETT M, POWLES TJ: Treatment of breast cancer with aromatase inhibitors - current status and future prospects. Br.J. Cancer (1989) 60:5–8.
   PubMed Web of Science ®Google Scholar
• DONNING PE: New endocrine drugs for treatment of advanced breast cancer. Acta Oncol. (1990) 29:379–386.
   PubMed Web of Science ®Google Scholar
• HAMILTON A, PICCART M: The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann. Oncol (1999) 10 (0377–384.
   PubMed Web of Science ®Google Scholar
• LONNING PE, DOWSETT M, POWLES TJ: Postmeno-pausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. (1990) 35:355–366.
   PubMedGoogle Scholar
• •Reviewing postmenopausal oestrogen disposition in detail.
   Google Scholar
• SLUIJMER AV, HEINEMAN MA, JONG FHD, EVERS JLH: Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorec-tomy. j Clin. Endocrinol Metab. (1995) 80:2163–2167.
   PubMed Web of Science ®Google Scholar
• HARADA N: Aberrant expression of aromatase inbreast cancer tissues. J Steroid Biochem. Mot. Biol. (1997) 61 (3-6):175–184.
   PubMed Web of Science ®Google Scholar
• VANLANDEGHEM AAJ, POORTMAN J, NABUURS M, THIJSSEN JHH: Endogenous concentration and subcel-lular distribution of estrogens in normal and malignant breast tissue. CancerRes. (1985) 45:2900–2904.
   Web of Science ®Google Scholar
• GEISLER J, BERNTSEN H, OTTESTAD L, LINDTJORN B,DOWSETT M, LONNING P: Neoadjuvant treatment with anastrozole ('Arimidex) causes profound suppres-sion of intra-estrogen levels. Proc. Am. Soc. an. Oncol (1999) 18:82a (Abstract 311).
   Google Scholar
• MASAMURA S, SANTNER SJ, GIMOTTY P, GEORGE J, SANTEN RJ: Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake. Breast Cancer Res. Treat. (1997) 42 (3) :215–226.
   PubMed Web of Science ®Google Scholar
• MILLER WR: Importance of intratumour aromatase andits susceptibility to inhibitors. In: Aromatase inhibition - then, now and tomorrow M Dowsett (Ed.), Partenon Publishing Group, London, UK (199043–53.
   Google Scholar
• JAMES VHT, REED MJ, ADAMS EF et al.: Oestrogen uptakeand metabolism in vivo. In: Oestrogens and the Human Breast. JS Beck (Ed.) Proc. R. Soc. Edin. (1989) 95B:185–193.
   Google Scholar
• SANTEN RJ, SAMOJLIK E, WELLS SA: Resistance of theovary to blockade of aromatization with aminoglu-tethimide. J. Clin. Endocrinol. Metab. (1980) Si (3):473–477.
   Google Scholar
• CELIO L, MARTINETTI A, FERRARI L et al.: Premenopausalbreast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. AntiCancer Res. (1999) 19 (313) :2261–2268.
   PubMed Web of Science ®Google Scholar
• DOWSETT M, STEIN RC, COOMBES RC: Aromatization inhibition alone or in combination with GmRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. (1992) 43:155–159.
   PubMed Web of Science ®Google Scholar
• REED MJ, TOPPING L, COLDHAM NG, PUROHIT A, GHILCHIK MW, JAMES VHT: Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors. J. Steroid Biochem. Mol. Biol. (1993) 44:589–596.
   PubMed Web of Science ®Google Scholar
• TURGEON C, GINGRAS S, CARRIERE MC, BLAIS Y, LABRIEF, SIMARD J: Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. J. Steroid Biochem. Mol. Biol. (1998) 65(1-6):151–162.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Pharmacology of new aromatase inhibi-tors. Breast (1996) 5:202–208.
   Web of Science ®Google Scholar
• GEISLER J, KING N, ANKER G et al.: In vivo inhibition ofaromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. (1998) 4:2089–2093.
   PubMed Web of Science ®Google Scholar
• DE JONG PC, VAN DE VEN J, NORTIER HVVR et al.: Inhibi- tion of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res. (1997) 57:2109–2111.
   Google Scholar
• MILLER WR, TELFORD J, LOVE C et al.: Effects ofletrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast (1998) 7:273–276.
   Web of Science ®Google Scholar
• GEISLER J, JOHANNESSEN DC, ANKER G, LONNING PE: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur. J Cancer (1996) 32A:789–792.
   PubMed Web of Science ®Google Scholar
• MURRAY R, PITT P: Aromatase inhibition with 4-0H androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat. (1995) 35:249–253.
   PubMed Web of Science ®Google Scholar
• ••First study revealing lack of complete cross-resistancebetween a non-steroidal aromatase inhibitor and a steroidal inactivator.
   Google Scholar
• THURLIMANN B, PARIDAENS R, SERIN D et al.: Third-line hormonal treatment with exemestane in postmeno-pausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II multicentre multinational study. Eur. J Cancer (1997) 33 (11):1767–1773.
   PubMed Web of Science ®Google Scholar
• HARPER-WYNNE C, COOMBES RC: Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur. J. Cancer (1999) 35(5):744–746.
   PubMed Web of Science ®Google Scholar
• LONNING PE, BAJETTA E, MURRAY R et al.: Activity of exemestane (Aromasi" in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin. Oncol. (2000) 18:2234–2244.
   PubMed Web of Science ®Google Scholar
• ••Revealing lack of complete cross-resistance between novel,potent non-steroidal aromatase inhibitors as anastrozole, letrozole and vorozole and exemestane.
   Google Scholar
• DI SALLE E, BRIATICO G, GIUDICI D et al.: Novel aromatase and 5-alpha-reductase inhibitors. J Steroid Biochem. Mol Biol. (1994) 49:289–294.
   PubMed Web of Science ®Google Scholar
• DI SALLE E, GIUDICI D, BRIATICO G, ORNATI G: Novel irreversible aromatase inhibitors. Ann. NY Acad. ScL (1990) 595:357–367.
   PubMed Web of Science ®Google Scholar
• DI SALLE E, BRIATICO G, GIUDICI D et al.: Novel aromatose and 5-alpha-reductase inhibitors. J Steroid Biochem. Mol Biol. (1994) 49:289–294.
   PubMed Web of Science ®Google Scholar
• BUZZETTI F, SALLE ED, LONGO A, BRIATICO G: Synthesis and aromatase inhibition by potential metabolites of ex emestane (5-methylenandrosta-1,4-diene-3,17-dione). Steroids (1993) 58:527–532.
   PubMed Web of Science ®Google Scholar
• GIUDICI D, ORNATI G, BRIATICO G, BUZZETTI F, LOMBARDI P, SALLE ED: 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem. (1988) 30:391–394.
   PubMedGoogle Scholar
• DI SALLE E, GIUDICI D, ORNATI G et al.:4-Arninoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J. Steroid Biochem. Molec. Biol. (1990) 37:369–374.
   Google Scholar
• ZACCHEO T, SALLE ED: Effect of the irreversiblearomatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother. Pharmacol. (1989) 25:95–98.
   PubMed Web of Science ®Google Scholar
• ZACCHEO T, GIUDICI D, ORNATI G, PANZERI A, SALLE ED: Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur. J. Cancer (1991) 27:1145–1150.
   PubMed Web of Science ®Google Scholar
• LONGCOPE C, BAKER S: Androgen and estrogen dynamics: relationship with age, weight and menopausal status. J. Clin. Endocrinol. Metab. (1993) 76:601–604.
   PubMed Web of Science ®Google Scholar
• ZILEMBO N, NOBERASCO C, BAJETTA E et al: Endocrino-logical and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J Cancer (1995) 72:1007–1012.
   PubMed Web of Science ®Google Scholar
• JOHANNESSEN DC, ENGAN T, SALLE ED et al.: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmeno-pausal breast cancer patients: A Phase I study. Clin. Cancer Res. (1997) 3:1101–1108.
   PubMed Web of Science ®Google Scholar
• GEISLER J, KING N, DOWSETT M et al: Influence of anastrozole (Arimidex*), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J Cancer (1996) 74:1286–1291.
   PubMed Web of Science ®Google Scholar
• HARRIS AL, DOWSETT M, JEFFCOATE SL, MCKINNA JA, MORGAN M, SMITH IE: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. (1982) 55:718–722.
   PubMed Web of Science ®Google Scholar
• POGGESI I, JANNUZZO MG, DISALLE E et al: Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynamics (PD) of a single oral dose of exemestane (Aromasin, EXE). Proc. Am. Soc. Clin. Oncol (1999) 18:193a (Abstract 741).
   Google Scholar
• LIEN EA, SOLHEIM E, UELAND PM: Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. (1991) 51:4837–4844.
   PubMed Web of Science ®Google Scholar
• JONES S, CHANG A, LUSCH C et al.: A Phase II confirma-tory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen and megace. Breast Cancer Res. Treat. (1998) 50:305 (Abstract 437).
   Google Scholar
• JONES S, VOGEL C, ARKHIPOV A et al.: Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin. Oncol. (1999) 17(11):3418–3425.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer (1998) 83 (6) :1142–1152.
   PubMed Web of Science ®Google Scholar
• •Phase III study comparing a novel potent aromatase inhibitor with conventional therapy in patients failing tamoxifen for metastatic breast cancer.
   Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin. Oncol. (1998) 16(2):453–461.
   PubMed Web of Science ®Google Scholar
• •See reference 49 for annotation.
   Google Scholar
• GERSHANOVICH M, CHAUDRI HA, CAMPOS D et al: Iztrozole, a new oral aromatase inhibitor: Random-ised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol. (1998) 9 (6):639–645.
   Google Scholar
• •See reference 49 for annotation.
   Google Scholar
• JONES S, BELT R, COOPER B et al.: A Phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refrac-tory to tamoxifen (Tam). Breast Cancer Res. Treat. (1998) 50:304 (Abstract 436).
   Google Scholar
• KVINNSLAND S, ANKER G, DIRIX LY et al: Antitumor efficacy of exemestane, a novel, irreversible, oral, aromatase inhibitor in postmenopausal patients with metastatic breast cancer (MBC) failing tamoxifen (TAM). Breast Cancer Res. Treat. (1997) 46:55 (Abstract 217).
   Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY et al: Ex emestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J. Clin. Oncol. (2000) 18:1399–1411.
   PubMed Web of Science ®Google Scholar
• ••Phase III study revealing superiority of exemestanecompared to megestrol acetate.
   Google Scholar
• PARIDAENS R, DIRIX LY, BEEX L et al: Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HI) of metastatic breast cancer (MBC) patients (Pts): results of a randomised Phase II trial. Proc. Am. Soc. Clin. Oncol. (2000) 19:83a (Abstract 316).
   Google Scholar
• •First-line data comparing exemestane with tamoxifen.
   Google Scholar
• COMPSTON JE: Prevention and management of osteoporosis. Current trends and future prospects. Drugs (1997) 53(5):727–735.
   Google Scholar
• DALLONGEVILLE J, MARECAUX N, ISOREZ D, ZYLBER-BERG G, FRUCHART J-C, AMOUYEL P: Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis (1995) 118:123–133.
   PubMed Web of Science ®Google Scholar
• POWLES T, EELES R, ASHLEY S et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 352 (9122):98–101.
   PubMed Web of Science ®Google Scholar
• VERONESI U, MAISONNEUVE P, COSTA A et al.: Preven-tion of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet (1998) 352 (9122) 93–97.
   PubMed Web of Science ®Google Scholar
• TONIOLO PG, LEVITZ M, ZELENIUCH-JACQUOTTE A et al.: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl. Cancer Inst. (1995) 87:190–197.
   PubMed Web of Science ®Google Scholar
• BERRINO F, MUTT P, MICHELI A et al.: Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. (1996) 88:291–296.
   PubMed Web of Science ®Google Scholar
• DORGAN JF, LONGCOPE C, STEPHENSON HE et al.: Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ. Health Perspect. (1997) 105:583–585.
   PubMed Web of Science ®Google Scholar
• THOMAS HV, KEY TJ, ALLEN DS et al.: A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br. J. Cancer (1997) 76 (7):401–405.
   PubMed Web of Science ®Google Scholar
• MACNEILL FA, JONES AL, JACOBS S, LONNING PE,POWLES TJ, DOWSETT M: The influence of aminoglu-tethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br. J Cancer. (1992) 66:692–697.
   PubMed Web of Science ®Google Scholar
• MACNEILL FA, JACOBS S, DOWSETT M, LONNING PE, POWLES TJ: The effects of oral 4-hydroxyandro stenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother. Pharmacol. (1995) 36:249–254.
   PubMed Web of Science ®Google Scholar
• LONNING PE, JACOBS S, JONES A, HAYNES B, POWLES T,DOWSETT M: The influence of CGS 16949A on periph-eral aromatisation in breast cancer patients. Br. J Cancer (1991) 63:789–793.
   PubMed Web of Science ®Google Scholar
• JONES AL, MACNEILL F, JACOBS S, LONNING PE, DOWSETT M, POWLES TJ: The influence of intramus-cular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur. J Cancer (1992) 28A:1712–1716.
   PubMed Web of Science ®Google Scholar
• MACNEILL FA, JACOBS S, LONNING PE, POWLES TJ, DOWSETT M: Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression. Br. J Cancer (1994) 69:1171–1175.
   PubMed Web of Science ®Google Scholar
• DOWSETT M, JONES A, JOHNSTON SRD, JACOBS S, TRUNET P, SMITH IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin. Cancer Res. (1995) 1:1511–1515.
   PubMed Web of Science ®Google Scholar